Piramal Pharma Ltd
Piramal Pharma Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #37 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Piramal Pharma Ltd Q2 FY26 key numbers
- Revenue
- Wholesale 2.0 AUM grew 43% YoY to Rs.11,295 crores, with active disbursements in real estate and mid-market loans.
As stated in Piramal Pharma Ltd's Q2 FY26 earnings call transcript · published 5 Aug 2026. Reported figures, not investment advice.
The short version
Piramal Finance aims to double its AUM to over Rs.1.5 lakh crores by FY28, implying strong growth in lending volumes. Piramal Finance targets doubling its AUM to over Rs.1.5 lakh crores by FY28, driving growth.
From Piramal Pharma Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Piramal Finance aims to double its AUM to over Rs.1.5 lakh crores by FY28, implying strong growth in lending volumes.
- Retail lending disbursements grew 36% YoY in Q2 FY26, with mortgages growing 37% YoY and crossing Rs.50,000 crores in AUM.
- Wholesale 2.0 AUM grew 43% YoY to Rs.11,295 crores, with active disbursements in real estate and mid-market loans.
- Growth business AUM was up 37% YoY, with consolidated AUM growing 22% YoY.
- The unsecured lending share is targeted to increase from 17% to 25% of the overall book over the medium term, indicating diversification.
- Technology and AI investments are driving higher sales productivity and better conversion of leads.
2 more points from Piramal Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Piramal Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Piramal Finance is focused on strategic investments in technology and AI (referred to as Piramal.ai) to boost sales staff productivity and improve lead conversion rates.
- There is an ongoing investment in expanding branches and embedding AI and analytics across operations.
- The company is in the process of launching a new gold loan business, which they will build slowly and organically over the next couple of years.
- No immediate capital raise is expected in FY26 or FY27 due to strong organic profit generation and capital release from legacy investment exits.
2 more points from Piramal Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Piramal Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Piramal Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Piramal Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.6K Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Piramal Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Piramal Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Piramal Pharma Ltd Q2 FY26 results?
Piramal Finance aims to double its AUM to over Rs.1.5 lakh crores by FY28, implying strong growth in lending volumes. Piramal Finance targets doubling its AUM to over Rs.1.5 lakh crores by FY28, driving growth.
What is Piramal Pharma Ltd share price analysis?
Piramal Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹27,530 Cr. Investors should review the full earnings analysis for detailed insights.
Is Piramal Pharma Ltd planning capital expenditure?
Piramal Finance is focused on strategic investments in technology and AI (referred to as Piramal.ai) to boost sales staff productivity and improve lead conversion rates.
Keep Piramal Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.